In recent trading session, FibroGen Inc (NASDAQ:FGEN) saw 4.44 million shares changing hands at last check today with its beta currently measuring 0.80. Company’s recent per share price level of $0.75 trading at -$0.02 or -2.95% at last check today assigns it a market valuation of $75.53M. That most recent trading price of FGEN’s stock is at a discount of -273.33% from its 52-week high price of $2.80 and is indicating a premium of 76.0% from its 52-week low price of $0.18.
For FibroGen Inc (FGEN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.2 in the current quarter.
FibroGen Inc (NASDAQ:FGEN) trade information
Upright in the red during last session for losing -2.95%, in the last five days FGEN remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $0.75 price level, adding 14.53% to its value on the day. FibroGen Inc’s shares saw a change of 41.57% in year-to-date performance and have moved 43.93% in past 5-day. FibroGen Inc (NASDAQ:FGEN) showed a performance of 48.73% in past 30-days.
Wall Street analysts have assigned a consensus price target of 28 to the stock, which implies a rise of 97.32% to its recent value today. Analysts have been projecting 28 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -3633.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -3633.33% for stock’s current value.
FibroGen Inc (FGEN) estimates and forecasts
This year revenue growth is estimated to rise 20.37% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 24.91M for the same.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.23% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 72.60% while estimates for its earnings growth in next 5 years are of 49.32%.
FibroGen Inc (NASDAQ:FGEN)’s Major holders
PRIMECAP MANAGEMENT CO/CA/ is the top institutional holder at FGEN for having 13.66 million shares of worth $12.19 million. And as of 2024-06-30, it was holding 13.6785 of the company’s outstanding shares.
The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 8.94 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.9508 of outstanding shares, having a total worth of $7.97 million.
On the other hand, Vanguard Horizon Fund-Capital Opportunity Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 3.98 shares of worth $2.93 million or 3.95% of the total outstanding shares. The later fund manager was in possession of 2.92 shares on Sep 30, 2024, making its stake of worth around $2.15 million in the company or a holder of 2.89% of company’s stock.
